Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Numico ephedra litigation

This article was originally published in The Tan Sheet

Executive Summary

The number of active ephedra cases at both GNC and Rexall Sundown increased by 10 since the beginning of March, "a continuation of the stable trend witnessed over the last 18 months," according to former parent company Royal Numico. The Dutch firm maintains that its occurrence-based insurance policy remains adequate in covering litigation risk, and that the probability of new lawsuits "is less likely" given that it halted ephedra sales last June. Numico reported 137 ephedra liability lawsuits in March (1"The Tan Sheet" March 8, 2004, p. 10)...

You may also be interested in...



GNC Liability In Ephedra Lawsuits Is Limited, Numico Says

Rexall Sundown and GNC have been named in 137 product liability lawsuits involving ephedrine alkaloid-containing dietary supplements, former parent company Royal Numico disclosed in a year-end financials release March 4

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation

Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel